ClinicalTrials.Veeva

Menu

Home Away From Home - Medical Outcomes (Aim 1)

Children's Hospital of Philadelphia (CHOP) logo

Children's Hospital of Philadelphia (CHOP)

Status

Completed

Conditions

Neutropenia
Bacteremia
Acute Myeloid Leukemia

Study type

Observational

Funder types

Other

Identifiers

NCT02774850
15-012074

Details and patient eligibility

About

Treatment for pediatric acute myeloid leukemia (AML) involves intensive chemotherapy regimens that result in periods of profound neutropenia leaving patients susceptible to severe infectious complications. Infectious complications are the leading cause of treatment related mortality among AML patients, but there are little clinical data to inform whether management of neutropenia post AML chemotherapy should occur in an outpatient or inpatient setting. The primary objective of this study is to compare the clinical effectiveness of outpatient versus inpatient management of neutropenia in children with AML.

Full description

This is a bidirectional observational cohort study.

Participants will be patients less that 19 years of age at diagnosis receiving or having received chemotherapy for AML from seventeen participating pediatric hospitals across the United States. There is no study intervention; this is a medical record abstraction study only. Investigators will abstract subjects medical record data over the study period in order to study clinical outcomes including the occurrence of bacteremia and time to the start of the next course in the chemotherapy regimen, in relation to neutropenia management strategy.

Enrollment

610 patients

Sex

All

Ages

Under 19 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Males or females of age less than 19 at diagnosis.
  2. Receipt or planned receipt of AML chemotherapy between January 1, 2012 and December 31, 2019.

Exclusion criteria

  1. Patients being treated for relapsed AML
  2. Patients with Acute Promyelocytic Leukemia (APML)
  3. Patients undergoing stem cell transplant (SCT)
  4. Patients receiving reduced intensity frontline chemotherapy

Trial design

610 participants in 2 patient groups

Early Discharge Management
Description:
Discharge to outpatient management during neutropenia within 3 days after chemotherapy completion in a given course
Inpatient Management
Description:
Remain hospitalized during chemotherapy-induced neutropenia

Trial documents
1

Trial contacts and locations

17

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems